Evaluation of adjuvanted pandemic H1N12009 influenza vaccine after one and two doses in young children

Pediatric Infectious Disease Journal

Volumn 30, Issue 5, 2011, Pages 402-407

  Scheifele, David W ^a   Ward, Brian J ^b   Dionne, Marc ^c   Vanderkooi, Otto ^d   Langley, Joanne M ^e   Dobson, Simon ^a   Li, Yan ^f   Law, Barbara ^g   Halperin, Scott A ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

children; H1N1 subtype; immunologic adjuvants; influenza A virus; influenza virus vaccines; pandemics

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CANADA; CHILD; DROWSINESS; DRUG EFFICACY; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; PANDEMIC; PRESCHOOL CHILD; PRIORITY JOURNAL; SHIVERING; SIDE EFFECT; SLEEP DISORDER; SWEATING; SWELLING; VOMITING;

EID: 79954887073     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182068f33     Document Type: Article

References (27)

1. Girard MP, Tam JS, Assossou OM, et al. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28:4895-4902.
2. Poland GA, Sambhara S. Vaccines against influenza A (H5N1): evidence of progress. JInfect Dis. 2008;198:629-631.
3. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008;7:241-247. (Pubitemid 351357958)
4. Fiore AE, Neuzil KM. 2009 influenza A (H1N1) monovalent vaccines for children. JAMA. 2010;303:73-74. doi: 10.1001/jama. 2009.1929.
5. Centers for Disease Control. Use of influenza A (H1N1) monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep. 2009;58(RR-10): 1-8.
6. Eggertson L. Canada can release pandemic vaccine earlier if necessary, chief public health officer says. Can Med Assoc J. 2009;181:E225-E226. doi: 10.1503/cmaj. 109-3065.
7. Arepanrix H1N1 [package insert]. Mississauga, ON, Canada: Glaxo Smith-Kline Inc; 2009.
8. Centers for Disease Control. Prevention and control of seasonal influenza with vaccines: recommendations ofthe Advisory Committee on Immuni-zation Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(RR-8):1-52.
9. Rumke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008;26:2378-2388.
10. A-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine. 2009;27:7428-7435.
11. Lerman SJ. Reactivity and immunogenicity of monovalent A/New Jer-sey/76 influenza virus vaccines in children. J Infect Dis. 1977;136(suppl): S563-S570. (Pubitemid 8293903)
12. French MB, Loeb MB, Richardson C, et al. Research preparedness paves the way to respond to pandemic H1N1 2009 influenza virus. Can J Infect Dis Med Microbiol. 2009;20:e63-e66.
13. Food and Drug Administration. Good clinical practice: consolidated guide-line. Fed Regist. 1997;62:25691-25709.
14. Lambert SB, Allen KM, Druce JD, et al. Community epidemiology of human metapneumovirus, human coronavirus NL63 and other respiratory viruses in healthy preschool-age children using parent-collected specimens. Pediatrics. 2007;120:e929-e937. (Pubitemid 47549537)
15. Committee for Proprietary Medicinal Products (CHMP). Note for guidance on harmonization ofthe requirements for influenza vaccines (CHMP/BWP/214/96). London, United Kingdom; Adopted March; 1997.
16. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted2009 influenza A H1N1 vaccineinchildren6-35 months. Vaccine. 2010;28:5837-5844.
17. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomized controlled phase 2 trials. Lancet. 2010;375:41-48.
18. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA. 2010;303:37-46.
19. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of ASO3B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomized, parallel group, multicenter study. BMJ. 2010;340:e2649. doi: 10.1136/bmj.c2649.
20. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6-to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006;118:e570-e578. doi: 10.1542/peds. 2006-0198. (Pubitemid 46091608)
21. Englund JA, Walter EB, Fairchok MP, et al. A comparison of 2 influenza vaccine schedules in 6-to 23-month-old children. Pediatrics. 2005;115: 1039-1047.
22. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563-571.
23. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet. 2007;370:580-589. (Pubitemid 47247854)
24. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28:4123-4129.
25. Miller E, Hoschler K, Hardelid P, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study Lancet. 2010;375:1100-1108. doi: 10.1016/50140-6736(09) 62126-7.
26. Ofri D. The emotional epidemiology of H1N1 influenza vaccination. N Engl J Med. 2009;361:2594-2595. doi: 10.1056/nejmp0911047.
27. Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis. 2004;38:678-688 (Pubitemid 38333864)